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ABSTRACT 
 
Oncolytic strains of vaccinia virus are currently in clinical development with clear evidence of safety 
and promising signs of efficacy. Addition of therapeutic genes to the viral genome may increase the 
therapeutic efficacy of vaccinia. We evaluated the therapeutic potential of vaccinia virus expressing 
the sodium iodide symporter (NIS) in prostate cancer models, combining oncolysis, external beam 
radiotherapy, and NIS-mediated radioiodide therapy.  
The NIS-expressing vaccinia virus, GLV-1h153, was tested in in vitro analyses of viral cell killing, 
combination with radiotherapy, NIS expression, cellular radioiodide uptake and apoptotic cell death 
in PC3, DU145, LNCaP and WPMY-1 human prostate cell lines. In vivo experiments were carried out 
in PC3  xenografts in CD1 nude mice to assess NIS expression and tumour radioiodide uptake. In 
addition, the therapeutic benefit of radioiodide treatment in combination with viral oncolysis and 
external beam radiotherapy was measured. 
In vitro viral cell killing of prostate cancers was dose- and time-dependent and was through 
apoptotic mechanisms. Importantly, combined virus therapy and ionising radiation did not adversely 
affect oncolysis. NIS gene expression in infected cells was functional and mediated uptake of 
radioiodide both in vitro and in vivo.  Therapy experiments with both xenograft and 
immunocompetent TRAMP mouse models showed that the addition of radioiodide to VV-NIS-
infected tumours was more effective than each single-agent therapy, restricting tumour growth and 
increasing survival. 
In conclusion, VV-NIS is effective in prostate cancer models. This treatment modality would be an 
attractive complement to existing clinical radiotherapy practice. 
 
  
INTRODUCTION 
The sodium iodide symporter (NIS) membrane protein is responsible for the uptake of iodide by the 
thyroid tissue. In cases of papillary and follicular thyroid cancer, radioactive Iodine-131 (131I) is used 
to ablate residual normal (and malignant) thyroid tissue after thyroidectomy, with high rates of 
efficacy (1). Targeted delivery of the NIS gene as a mode of cancer gene therapy represents an 
opportunity to bring the proven therapeutic potential of I131 to bear against other cancer types. 
Oncolytic virotherapy exploits the natural or engineered affinity of certain viral strains selectively to 
infect and replicate in cancer cells and, in doing so, to kill them. In clinical testing, they have been 
shown to have excellent safety profiles and promising signs of efficacy(2, 3). The adenovirus H101 
has been approved in China for use in head/neck cancer(4). A positive phase III trial of talimogene 
laherperepvec (T-Vec, herpes simplex virus type 1) has been reported(5)  and this agent received 
approval by the European Medicines Agency in October 2015 for patients with malignant 
melanoma(6).  
Vaccinia virus belongs to the Poxviridae family and possesses a large linear double-stranded DNA 
genome consisting of approximately 250 genes, with capacity for insertion of therapeutic 
transgenes, such as the NIS gene(7). Vaccinia has been administered widely as the smallpox vaccine 
and, as such, it has an excellent safety profile(8). It has also been examined extensively in attenuated 
forms as an oncolytic agent with comparable safety(9). The complex life cycle of Vaccinia includes 
dual mechanisms of infection by separate forms of infectious particles. Intracellular mature virions 
(IMV) are the main product of viral lysis and extracellular enveloped virions (EEV) are actively shed 
by infected cells (10). Compared to other agents, Vaccinia offers a number of potential advantages 
including rapid replication in and lysis of infected cells, the ability to achieve high levels of viral gene 
expression, the capacity to spread cell-to-cell and the fact that its activity is unhindered by 
hypoxia(11) and therapeutic irradiation(12). Genetic modification of Vaccinia to express the NIS gene 
represents a further refinement of its therapeutic potential by giving it the capacity to drive cellular 
131I uptake for direct killing of infected cells and indirect killing of neighbouring cells within the 
0.8mm range of the emitted β particles (13). Previous studies have explored the potential of NIS, 
delivered by a range of oncolytic viruses including measles, HSV and VSV as a therapeutic reporter 
gene and as a therapeutic agent (14-18). Oncolytic vaccinia virus has been studied in-vitro in a range 
of tumour types, enabling PET and SPECT-CT observation of viral kinetics using a variety of 
radioiosotopes including 131I, 124I and 99mTc (19-21). This has been shown this to be a viable imaging 
method in a phase I/II trial of MV-NIS in ovarian cancer patients (18) and would be a useful safety 
monitoring tool to confirm that viral biodistribution in other human trials is as expected. 
Furthermore, oncolytic vaccinia enabled NIS therapy has shown additional benefit of 131I 
administration in pancreatic and breast cancer models (21, 22).  
Prostate cancer is the commonest form of male cancer and the second highest cause of cancer death 
in the United States, with approximately 240,000 new cases and 28,000 deaths annually(23). 
Currently, prostate cancer treatment typically involves radical prostatectomy or radiotherapy with 
good survival outcomes for the 90% of patients whose disease is diagnosed at the local/regional 
stage (1). However, the side effects of such treatments can be significant and include incontinence, 
bowel complications and erectile dysfunction, with associated long-term detriment to quality of life. 
The prognosis for those patients who develop castration resistant disease is poor(24). Despite recent 
advances in medical therapies (25-28), men with prostate cancer will ultimately develop treatment-
refractory, incurable disease. Therefore, there is a need for novel therapies with improved side-
effect profiles in loco-regional disease and improved efficacy in metastatic disease. Prostate cancer 
has been targeted for NIS gene therapy in numerous pre-clinical studies (29). Using adenovirus as a 
vector, NIS gene expression in prostate tissue has, in a Phase 1 trial, proven the 99mTc imaging 
approach to be both safe and feasible (30). Further study is ongoing (31). To date, no human trials 
have studied the potential of oncolytic viral therapy to additionally enable NIS 131I therapy. 
In this study, we examine the therapeutic potential of the Vaccinia virus, GLV-1h153, as an oncolytic 
agent and as a vector for targeting NIS gene therapy to prostate cancer cells in vitro and in vivo. We 
demonstrate efficient time- and dose-dependent marker gene expression and oncolysis of a panel of 
human prostate cell lines and confirm that these virally-mediated effects are not affected by 
combination with radiotherapy. Combined GLV-1h153 and radiation therapy is shown to enhance 
apoptosis of prostate cancer cells. NIS is shown to be both expressed and functional, enabling the 
prostate cells to concentrate radioiodide. In vivo NIS gene expression and iodide uptake is 
demonstrated in xenograft tumours of PC3 cells and therapeutic experiments show the combination 
of virus and 131I to be significantly more effective against these tumours than either therapy alone. In 
the immunocompetent TRAMP model of prostate cancer this radio-virotherapeutic approach also 
proved to be effective.  
MATERIALS AND METHODS 
 
Cell lines 
The following cell lines were used in these studies: CV1 Monkey kidney fibroblasts (ATCC, USA); 
Human prostate cancer cell lines PC3, DU145, LNCaP and WPMY-1 (Obtained from the laboratory of 
Prof. Pandha, University of Surrey, UK). Murine prostate cancer cell lines TRAMP-C1 (ATCC, USA), 
TRAMP-C2 (Obtained from the laboratory of Prof. Vile, Mayo Clinic) and TRAMP-C3 (ATCC, USA).  
 
Virus Stock 
GLV-1h153 (Genelux GmbH, Germany) is an oncolytic Lister strain Vaccinia virus attenuated by 
insertion of LacZ (beta-galactosidase), hNIS (sodium iodide symporter) and RUC-GFP (fusion gene of 
Renilla luciferase and green fluorescent protein) into the J2R, A56R and F14.5L loci, respectively. 
 
Viral Plaque Assays 
Viral titres were determined by viral plaque assay (VPA). Monolayers of CV1 cells in 24-well plates 
were treated with serial dilutions of the viral solution to be titred and incubated for 24 hours. Cells 
were fixed with 2% formaldehyde (Sigma-Aldrich, USA)/0.2% glutaraldehyde (Sigma-Aldrich, USA) in 
phosphate-buffered saline (PBS, Sigma-Aldrich, USA) and stained for 4 hours with 5 mM potassium-
hexa-cyanoferrat III (Sigma-Aldrich, USA), 5 mM potassium-hexa-cyanoferrat II-tri-hydrate (Sigma-
Aldrich, USA), 2 mM magnesium chloride-hexahydrate (Sigma-Aldrich, USA)and 0.6 mg/mL 5-Bromo-
4-chloro-3-indolyl β-D-galactopyranoside (X-Gal , CalBioChem, UK) in PBS.  Cells were then washed 
with ultrafiltered water and dried. Macroscopic X-gal-stained viral plaques were counted manually.  
 
MTT Proliferation Assay 
Cell proliferation was measured by plating 1 x 104 cells/well in 100 µL Dulbecco’s modified Eagle’s 
medium (DMEM, Life Technologies, USA) and incubating overnight before adding 100 µL virus in 
DMEM, diluted to the relevant multiplicity of infection (MOI).  At the experimental end-point, 20 µL 
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich, USA) at 5 
mg/mL in PBS was added. Medium was aspirated from each well after 4 hours of incubation at 37 °C 
and crystals were solubilised in 200 µL of dimethyl sulfoxide (DMSO, Fisher Scientific, UK). 
Absorbance was measured at 550 nm by a SpectraMax M5 plate reader (Molecular Devices Ltd., UK). 
 
SRB Cytotoxicity Assay  
Cell viability was quantified by fixing cells with 10% trichloroacetic acid (TCA) (Sigma-Aldrich, USA) 
and staining with 0.05% sulforhodamine B (SRB) in 1% acetic acid (Sigma-Aldrich, USA). The SRB 
bound to cells was dissolved with 10 mM TRIS and absorbance was measured at 510 nm on a 
SpectraMax M5 plate reader. 
 
Clonogenic Assay  
Cells were plated at 5 × 105 in a T25 flask (Corning, USA). The next day, cells were irradiated at 2 Gy 
and 6 hours later infected with GLV-1h153 at MOI of 0.01. Forty-eight hours post-treatment, cells 
were washed in PBS, trypsinized and counted using a haemocytometer. Cells were then plated into 
6-well dishes at 400-800 cells/well.  After 10-14 days, plates were stained with 0.2% crystal violet 
(Sigma-Aldrich, USA) in 7% ethanol and the colonies consisting of approximately 50 cells or greater 
were counted manually. 
 
Caspase 3/7 Luminometry Assay 
Relative levels of Caspase 3/7 activation 48 hours post-infection were measured by Caspase-Glo® 3/7 
Assay (Promega, UK), in which a proluminescent caspase-3/7 DEVD-aminoluciferin substrate is 
cleaved by active caspases 3/7, producing free aminoluciferin as a luciferase substrate. The detected 
levels were normalised according to the proportion of surviving cells, as determined by a tandem 
MTT assay carried out simultaneously. 
Western Blotting 
Cells were plated at 0.5 × 106 in 60 mm dishes. Following various treatments, cells were harvested in 
ice-cold PBS, pelleted and resuspended in radioimmunoprecipitation assay buffer [50 mM Tris (pH 
7.5), 150 mM NaCl, 1 % NP40, 0.5 % sodium deoxycholate, and 0.1 % SDS (all Sigma-Aldrich, USA)] 
plus protease inhibitors for measurement of caspase cleavage and JNK activation. For NIS 
expression, cell pellets or tumors (for in vivo studies) were harvested and suspended in lysis buffer 
containing 30 mM Tris (pH 7.5), 150 mM NaCl, 5 mM CaCl2, 150 mM MgCl2, 0.5% NP40 plus protease 
inhibitors (Roche Diagnostics GmbH, Mannheim, Germany). Cells or tumors were then sonicated and 
centrifuged at 13,200 rpm/4 °C for 20 minutes to remove cell debris. Protein concentration of the 
lysates was determined using the BCA protein assay reagent (Life Technologies, USA). Thirty 
micrograms of each protein sample were resolved on SDS-polyacrylamide gels (10-12%) and 
transferred to a polyvinylidene difluoride Hybond-P membrane (Amersham, UK). Immunodetections 
were performed using anti-caspase 3 (Cell Signaling, USA), anti-phosphorylated JNK (Thr 183/Tyr 
185, Cell Signaling, Massachusetts, USA) rabbit polyclonal antibody in conjunction with a horseradish 
peroxidase (HRP)-conjugated anti-rabbit or anti-mouse secondary antibody (GE-Healthcare, UK). 
Equal loading was assessed using α-tubulin (Sigma Aldrich, USA) mouse monoclonal primary 
antibodies. The Super Signal chemiluminescent system (Life Technologies, USA) or Immobilon 
Western chemiluminescent HRP substrate (Merck Millipore, Germany) were used for detection. 
Quantification was performed using ImageJ software (LOCI, USA). 
 X-Irradiation 
All irradiations were done using an AGO HS MP1 X-ray unit (AGO X-Ray Ltd, UK) at 250 kV and at a 
dose rate of 0.6 Gy/min, as measured directly by a PTW UNIDOS E-digital dosimeter (PTW Freiburg 
GmbH, Germany). Cells were irradiated in 24- or 96-well plates (Thermo Fisher Scientific, USA) in 
single fractions up to 5 Gy.   
CPRG β-gal expression assay 
Cells were treated in 96-well plates (Thermo Fisher Scientific, USA) and at the experimental endpoint 
lysed using 0.1% Triton X-100 (Sigma-Aldrich, USA) and 250 mM Tris pH 8.5 (Sigma-Aldrich, USA) in 
water and frozen for at least 1 hour at -80 °C. Upon thawing, lysates and standards were mixed 1:1 
with CPRG staining solution (60 mM disodium phosphate, 1 mM magnesium sulphate, 10 mM 
potassium chloride, 50 mM 2-mercaptoethanol, 1 mg/mL chlorophenolred-β-D-galactopyranoside 
(CPRG) (all Sigma-Aldrich, USA)) and incubated at 37 °C until a gradient was visible in the standards 
(at approximately 2 hours). Absorbance was then measured at 578 nm in a SpectraMax M5 plate 
reader. Sample β-gal concentrations were interpolated from the standards by non-linear regression 
in GraphPad Prism v5 (GraphPad Software, USA). 
NIS mRNA qRT-PCR assay 
Cells were treated in 24-well plates for 24 hours before lysis and collection of RNA using RNeasy mini 
kit (Qiagen, UK). cDNA was prepared using a SensiFAST cDNA synthesis kit (Bioline Reagents Limited, 
UK) and qPCR performed using an SLC5A5 (NIS gene) specific TaqMan gene expression assay kit 
(Applied Biosystems, UK) and run on a StepOne Plus thermal cycler (Applied Biosystems, UK). 
Radioiodide Uptake Assay 
Cells were plated in 24-well plates (Nunc) at 1 x 105 cells/well in 500 µL DMEM and incubated 
overnight before infection with virus. At the experimental endpoint, 1 µCi (0.37 MBq) of 131I (Perkin 
Elmer, USA) was added to each well for 1 hour. Duplicate wells received 131I pre-mixed with 50 µM 
potassium perchlorate (Sigma Aldrich, USA). All wells were washed with copious amounts of PBS 
before detaching cells with 100 µL 1 M sodium hydroxide (Sigma Aldrich, USA) for 20 minutes. 
Gamma emissions from each sample were measured with a Wallac 1470 Wizard automatic gamma 
counter (Perkin Elmer, USA). 
Confocal Microscopy 
Cells were seeded into glass bottomed 35 mm dishes (MatTek Corporation, USA), and infected at an 
MOI of 0.01 24 hours later. Following a 24 hour infection period cells were then irradiated or the 
media was spiked with 5 µCi (1.85 MBq) of  131I. Cells were then incubated for 1 hour to allow H2Ax 
foci to form at the site of any DNA double-strand breaks induced, before being fixed in 4 % 
paraformaldehyde. Permeabilised with 0.2 % Triton X-100 in PBS for 20 min. H2aX foci were 
detected by a 1:200 dilution of rabbit anti-γH2aX primary antibody (Cell signalling, USA) incubated at 
4 °C overnight and Alexafluor-546 conjugated secondary antibody (Life Technologies, USA) diluted 
1:1000 at room temperature for 90 minutes. DNA was stained with 1:10,000 dilution of DAPI (Life 
technologies, USA). Quantification of the confocal images was done using CellProfiler 2.0 (Broad 
Institute, USA) software configured to recognise cell nuclei, GFP expressing cells and γH2Ax foci. The 
bystander cells were classified as cell nuclei lying wholly or partially within a 20 µm perimeter of GFP 
positive cells. 
In vivo Xenograft Studies 
Xenograft tumours (PC-3) were established by injecting 3 x 106 cells in 100 µL PBS subcutaneously in 
to the right flank of CD1 nude mice (Charles River Ltd, UK). Tumours were allowed to grow to 5-8 
mm in diameter and randomly allocated to treatment groups before beginning therapy. All animal 
work was carried out in compliance with UK Home Office regulations and under the scrutiny of the 
Institutional Review Board. 
Virus at the relevant concentration was administered intratumourally in 100µL PBS. Control animals 
received intratumoural injections of PBS alone. A single cutaneous puncture site and multiple 
intratumoural injection tracks were used to improve the distribution of injectate within the tumour. 
After 48 hours, 131I was administered by intraperitoneal injection (1 mCi (37 MBq) in 100 µL Hanks 
balanced salt solution (HBSS). 
Prior to administration of 131I, cage water was supplemented with 5% Lugol’s iodine solution (Sigma-
Aldrich, USA) for a minimum of 72 hours to attempt to saturate the thyroid gland with non-
radioactive iodide. This was replaced with normal drinking water 24 hours before 131I administration.  
Prior to tumour irradiation, mice received intraperitoneal injections of 100 µL of a 1:1:4 solution of 
Hypnorm (0.315 mg/mL fentanyl citrate and 10 mg/mL fluanisone; Janssen Pharmaceutica, USA), 
Hypnovel (5 mg/mL midazolam; Roche Products Ltd., Germany) and sterile water. 
Tumours were measured twice weekly in two dimensions using Vernier callipers and the volume was 
estimated using the formula: (Width x Length2)/2. 
For some experiments, tumour iodide uptake was measured by excision of the whole tumour and 
other tissues, and detection of gamma emissions using a Wallac 1470 Wizard automatic gamma 
counter (Perkin Elmer, USA). Results were normalised to the weight of the tumour/thyroid gland. 
GFP imaging was performed under inhalational anaesthesia (Vetflourane, Virbac Animal Health, 
France) with IVIS Lumina II imaging system (Caliper Life Sciences, USA). GFP fluorescence was 
detected using an excitation wavelength of 465 nm, a GFP-specific emission filter and an exposure 
time of 0.2 seconds. Bioluminescence was measured following IP administration of 100 µg h-
Coelenterazine-SOL (Nanolight Technologies, USA) immediately prior to imaging.  
TRAMP mouse in vivo studies 
The TRAMP (Transgenic Adenocarcinoma of the Mouse Prostate) mouse model was acquired from 
the Jackson Laboratory, USA. A breeding colony was established in the C57BL/6 background to 
produce heterozygous TRAMP males. Characterisation studies were carried out to observe the rate 
of tumour growth and select a time point for intervention based on the level of disease progression. 
Animals were culled at a range of time points and the prostate gland and seminal vesicles were 
dissected and observed histologically. Animals were found to develop prostate adenocarcinoma, as 
well as seminal vesicle epithelial stromal tumours that resemble phyllodes tumours of the human 
breast, as has been previously described in this model(32). 
Therapeutic experiments were carried out on heterozygous TRAMP males aged 29-31 weeks. 
Animals received 5 x 107 PFU of GLV-1h153 in 100 µL PBS by tail vein injection. Five days later, 
animals received 1 mCi 131I in 100 µL HBSS by intraperitoneal injection. All groups were given Lugol’s 
iodine supplement as described previously. The animals were observed long-term for disease 
progression and culled if showing signs of discomfort. Animals with abdominal tumours not causing 
any obvious discomfort were culled if the tumour was palpable and over 1 cm in diameter. Post 
mortem dissection of all mice was done to enable histological analysis of the extent of the tumour 
progression and metastasis. Tissues were paraffin embedded and sectioned before Shandon™ Harris 
Hematoxylin (Thermo Fisher Scientific, USA) and eosin (Leica Biosystems, Germany) staining, and 
immunohistochemical staining with Ki67 (Dako UK ltd., UK) and probasin (Santa-Cruz Biotechnology 
inc., USA) antibodies with Shandon Gill Hematoxylin counterstain (Thermo Fisher Scientific, USA). 
Statistical Analysis 
All statistical tests including t-tests, one way ANOVA, two-way ANOVA with Bonferroni post-tests, 
Kaplan Meier survival analysis and associated Log-Rank tests were performed using GraphPad Prism 
version 5 (GraphPad Software, USA). 
RESULTS 
GLV-1h153 cytotoxicity in prostate cancer cell lines 
A panel of four prostate cancer cell lines, DU145, PC3, LNCaP and WPMY-1, was tested for their 
susceptibility to the GLV-1h153 virus. The cells were infected with virus at MOIs ranging between 
0.0001 and 10 for periods ranging from 24 to 72 hours. Reduction in cell proliferation relative to 
uninfected controls was then assessed by MTT assay. The virus was effective against all four cell 
lines, killing in a dose- and time-dependent manner (2-way ANOVA P < 0.0001 for both virus and 
time factors as sources of variation for each cell line individually) (Fig 1). DU145, LNCaP and WPMY-1 
showed a positive interaction between time and dose (2-way ANOVA P < 0.0001), producing 
increased cell death over time. PC3 were somewhat resistant to this effect, especially at MOI 0.001 
to 0.1. 
NIS mRNA expression in GLV-1h153-infected cells 
The cell lines DU145, PC3 and WPMY-1 were infected with GLV-1h153 MOIs ranging between 0.001 
and 1 for 24 hours before levels of NIS mRNA were quantified by qRT-PCR. Levels of mRNA detected 
correlated positively with increasing MOI of the virus (Supplementary Figure 1). There was no NIS 
mRNA detectable in the uninfected cells. 
In vitro 131I uptake in GLV-1h153-infected cells 
Confocal microscopy was used to look directly at WPMY-1, PC3 and DU145 cells during infection to 
determine the levels of H2Ax foci (DNA double-strand break marker) induced by either viral infection 
or 131I uptake (Fig 2A). Cells irradiated with 2 Gy exhibited H2Ax foci, while those incubated with 131I 
showed very few. However when infected cells were incubated with 131I many more H2Ax foci were 
observed. These images were then quantified to compare levels of DNA damage in sub-groups of 
cells (Fig 2B). Firstly infected cells, determined by GFP expression, were compared to non-infected 
cells. Infected WPMY-1 and PC3 cells were more susceptible to DNA damage by external beam 
irradiation. DU145 showed a similar profile although this was not statistically significant. In infected 
DU145 cells incubated with 131I, non-infected cells had a greater number of H2Ax foci, though this 
was not seen in WPMY-1 and PC3, where infected cells had a greater proportion of foci.  
With infected cells accumulating iodide and appearing to cause an increase in DNA damage, it was 
hypothesised that uninfected cells closer to infected ones should receive a greater dose of radiation 
than those further away, according to the inverse square law of radiation. We hypothesised that this 
would account for uninfected DU145 cells receiving a greater proportion of the 131I induced DNA 
damage than the infected cells. To evaluate this, the confocal images were again quantified, with a 
perimeter of 20 µm around infected cells in which any other cell nuclei would be classed as a 
‘bystander’, cells wholly outside the perimeter were ‘non-bystanders’ and infected cells were 
excluded. The bystander DU145 cells exhibited 6-fold more H2Ax foci than non-bystanders when 
exposed to 131I. This effect was also seen to a lesser extent with external beam radiation, suggesting 
that infection somehow radiosensitises the non-infected DU145 cells, though this was not 
statistically significant. WPMY cells did show a significant radio-sensitisation effect on bystander cells 
while PC3 did not. No significant bystander effect was observed in the WPMY or PC3 bystander cells 
exposed to 131I, although in these cell lines there were few foci in non-infected cells. As another, 
more general, measure of bystander effect, the images were quantified to compare the total 
number of H2Ax foci in the field of view to the total number of infected cells (Supplementary Figure 
2). Comparison by this method revealed a positive correlation between number of infected cells and 
H2Ax foci in DU145 cells, and no such correlation in WPMY-1 and PC3, thus supporting the above 
data. 
To verify the functional expression of the NIS transgene, in vitro iodide uptake assays were 
performed. Cells were irradiated with 5 Gy (or not) and then infected at MOIs of 0.01, 0.1 and 1 for 
24 or 48 hours. At this time, they were treated with 131I and radioiodide uptake was measured by 
gamma emissions from the cells. At 24 hours, all four cell lines showed NIS expression and iodide 
uptake at MOI 1, with a highly significant difference (2-way ANOV A P < 0.001) compared to cells 
treated with the competitive inhibitor of iodide uptake (potassium perchlorate) (Fig 2C). LNCaP also 
had significant uptake with MOI 0.1 at 24 hours (2-way ANOVA P <0.01). At 48 hours, all four cell 
lines showed an increase in iodide uptake at MOI 0.1 compared to that seen at 24 hours. Cells 
irradiated with 5 Gy showed little difference in the levels of iodide uptake except in DU145 at 48h 
where the level of uptake at an MOI of 0.1 was significantly lower. 
GLV-1h153 cytotoxicity in combination with ionising radiation 
To confirm that ionising radiation does not affect the ability of the virus to replicate, express 
transgenes and cause cell death in prostate cells, external beam irradiation was used as a substitute 
for 131I to allow controlled and equal exposure of all cells to ionising radiation. The range from 1 to 5 
Gy was selected to represent radiation doses that would not immediately kill the cells and should 
allow viral infection to be productive and potentially show synergy as previously published in other 
models (12, 33). The panel of cell lines was infected with MOIs ranging between 0.01 and 1, either 
four hours pre- or post-irradiation with 1, 3 or 5 Gy. Cells were incubated for periods of 24, 48 and 
72 hours and cell proliferation was assessed by MTT assay.  Cells irradiated prior to infection all 
showed a significant dose-dependent effect of virus at all time-points (2-way ANOVA P < 0.0001). 
Irradiation had a significant dose-dependent effect in LNCaP and WPMY-1 at 24 and 48 hours; 
LNCaP, WPMY-1 and PC3 at 48 hours (Supplementary Figure 3); and all four cell lines at 72 hours (2-
way ANOVA P < 0.0001) (Fig 3A). Irradiation never significantly reduced the viral effect. The 
alternative scheduling, irradiation four hours post-infection, yielded broadly similar results and 
indicated no benefit of one schedule over the other (Supplementary Figure 4). 
The SRB assay was also used to confirm the results observed with the MTT assay. Radiation was 
delivered four hours pre-infection and cell number was measured at 48 hours. These data also 
showed a significant radiation dose effect (2-way ANOVA P < 0.0001) and confirmed that the viral 
effect is unaffected by irradiation (Fig 3B). 
Clonogenic assays were performed with the two cell lines that were capable of colony formation 
(LNCaP and PC3) in order to determine the longer-term effects of the virus-radiation combination on 
cell survival. These data show that the clonogenic potential of cells was reduced by irradiation and 
by viral infection in dose-dependent fashion (for each agent). The combination of the two 
treatments reduced the clonogenic capacity of the cells to a greater extent than either treatment 
alone (Fig 3C).  
Expression of viral transgenes in combination with ionising radiation 
CPRG assay was used to confirm that viral transgene expression was not adversely affected by 
irradiation. The cell line panel was irradiated with between 1 and 5 Gy four hours prior to infection 
with MOIs ranging between 0.016 and 1. β -galactosidase gene expression was measured at 24, 48 
and 72 hours. At 24 hours (Fig 4A, B), all four cell lines showed statistically significant viral dose-
dependent expression of β–galactosidase (2-way ANOVA P < 0.0001) and no consistent significant 
irradiation effect (positive or negative) on gene expression. Gene expression levels at MOI 1 were 
greatest with LNCaP (994 pg/µL), followed by WPMY-1 (275 pg/µL), PC3 (150 pg/µL) and DU145 (103 
pg/µL). At 48 and 72 hours (Supplementary Figure 5) the gene expression continued to increase. At 
72 hours gene expression at the highest MOI had dropped relative to the 48 hour time point, 
correlating with the cell death shown in Figure 1. The inverse treatment schedule of GLV-1h153 
infection four hours prior to irradiation showed a similar gene expression profile (Supplementary 
Figure 6). 
Induction of apoptotic cell death by GLV-1h153 and ionising radiation 
The panel of cell lines was analysed for the apoptotic response to virus at MOIs between 0.01 and 1 
and irradiation between 1 and 5 Gy. The response varied widely between cell lines (Fig 5A). By 
Caspase Glo3/7 assay, DU145 showed strong (up to 5.5-fold) Caspase-3/7 induction in response to 
virus (2-way ANOVA P < 0.0001), but no significant radiation effect was observed. LNCaP also had a 
small but significant response (up to 1.4-fold) to virus only (2-way ANOVA P < 0.0001). PC3 had no 
Caspase-3/7 response to either virus or irradiation; and WPMY had a significant response (up to 2-
fold) to irradiation only (2-way ANOVA P = 0.0137).  
Western blots for the active cleaved form of Caspase-3 correlated closely with the Caspase-Glo data, 
showing no functional Caspase-3 in PC3 cells and replicating the patterns of sensitivity observed in 
the remaining cell lines. It has previously been published that synergy between radiation and 
vaccinia virus in BRAF mutant melanoma is dependent on signalling via JNK and TNF-α(33). Phospho-
JNK western blots showed that JNK becomes highly active in response to virus in all cell lines, though 
no clear radiation effect was observed (Fig 5B).  
Combination of viral infection and irradiation consistently activated markers of apoptosis to high 
levels, with the combination of viral infection and 131I showing higher levels of PARP-1 cleavage than 
the combination with external beam radiation in DU145 and LNCaP (Fig 5C and Supplementary 
Figure 7). The effects were approximately equal in PC3. Despite PC3 seemingly lacking functional 
Caspase-3, cleavage of PARP-1 and expression of γH2Ax both indicate that apoptosis is occurring in 
this cell line. 
In-vivo viral gene expression and 131I uptake in GLV-1h153-infected tumours 
The PC3 cell line was selected for in vivo experiments, as it had high levels of viral gene expression 
persisting for 72 hrs post-infection in vitro. Xenografts in CD1 nu/nu mice were allowed to grow to 5-
10 mm in diameter before intratumoural injection of virus (1 x 106 PFU) or control injection. After 48 
hours, 131I was administered intraperitoneally as described. A further 48 hours later, tumour iodide 
uptake and GFP expression were measured (Fig 6A, B). Tumours injected with virus had gamma 
emissions 2.7 fold higher than control tumours (T-test P < 0.05). There was no significant difference 
in emissions from thyroid tissue between the two treatment groups. In tumours injected with virus, 
GFP expression was observed at low levels. Bioluminescence generated by viral Renilla luciferase 
indicated that viral replication and gene expression is limited to the tumour tissue only (Fig 6D). 
Uptake of 131I in non-NIS expressing tissue was minimal, with tumour tissue uptake being twice that 
in the blood (Supplementary Figure 8). 
GLV-1h153 and 131I combined treatment in PC3 xenografts 
PC3 xenografts in CD1 nu/nu mice were allowed to grow to 5-10 mm in diameter. Mice were divided 
into four groups, two of which received intratumoural injection of virus. Forty-eight hours later, one 
treated group and one non-treated group received 131I. Tumours treated with 131I only continued to 
grow at the same rate as the controls (Log-Rank P = 0.41). Virus alone slowed growth marginally and 
significantly improved survival to 60% at study termination, 60 days post-treatment (Log-Rank P < 
0.05). The virus and 131I treatment combination stabilised tumour growth and improved survival at 
study termination to 80% versus 0% in the control group (Log-Rank P = 0.004), with all surviving mice 
having stable or completely regressed tumours (Fig 6C). 
GLV-1h153 biodistribution from PC3 xenografts 
PC3 xenografts in CD1 nu/nu mice were allowed to grow to approx. 10 mm in diameter and then 
received intratumoural injection of virus (1x106 PFU). At one hour and at 4, 6 and 9 days post-virus 
administration 100 µg coelenterazine, the substrate for the viral encoded Renilla luciferase, was 
administered to the animals to allow bioluminescent detection of areas of viral gene expression (Fig 
6D and Supplementary Figure 9). These images show that viral replication was limited to the tumour 
tissue only and did not disseminate to other tissues. Low levels of gene expression were detected in 
75% of the animals at the one hour time point, and the level of gene expression increased markedly 
over the following time points. 
 
GLV-1h153 in TRAMP-C cell lines 
Following the positive results from the PC3 model in immunodeficient CD1 nu/nu mice, we 
considered that a fully immunocompetent model would more closely reflect the challenges faced by 
the virus in a clinical setting. The TRAMP transgenic model of murine prostate cancer was selected.  
To test the species specificity of GLV-1h153, three cell lines derived from TRAMP tumours (TRAMP-
C1, -C2, -C3) were challenged with the virus. The TRAMP-C cell lines were susceptible to infection 
and viral GFP expression was observed 24 hours post infection (Fig 7A, Supplementary Figure 10). 
DNA damage due to radioiodide uptake was also seen in both infected cells and bystander cells. 
In cell proliferation assays (Fig. 7B), the TRAMP-C1 line showed some resistance to viral infection and 
a slower death as compared to the data for the human cell lines at 48h post-infection. Tramp-C2 and 
-C3 showed improved viral cell kill. Infection following exposure to ionising radiation appeared to 
produce an additive effect on cell death in most cases. 
GLV-1h153 and 131I combined treatment in TRAMP mice 
The TRAMP mouse strain was used to evaluate the efficacy of the virus in an immunocompetent 
mouse model of prostate cancer. Pilot experiments showed that TRAMP mice aged between 29-31 
weeks showed clear histological signs of either a tumour or extensive neoplasia in the prostate and 
associated tissues i.e. the seminal vesicles as has been described(32). It was, therefore, selected as 
the optimal time point for intervention. Animals treated with virus exhibited transient pox lesions in 
the skin ~7 days post-treatment, indicating the replicative ability of the virus in an 
immunocompetent host for a prolonged period post-administration. These lesions healed without 
intervention within ~7 days (Supplementary Figure 11). Intervention with GLV-1h153 alone extended 
the median survival from 50.5 days to 123.5 days, as compared to control animals (Log-Rank: 
P=0.007) (Fig. 7C). The addition of 131I to the viral intervention further improved survival to 195 days, 
an additional 71.5 days over the virus alone (Log Rank: P=0.0169). Comparison of the tumour growth 
curves show the addition of 131I to the viral therapy caused a significant reduction in the growth rate 
of the tumour (P=0.288). 
Histological analysis revealed extensive hyperplasia of the prostate (Figure 7D) and seminal vesicles, 
with metastatic disease present in the lung, liver and lymph nodes (Supplementary figure 12-14). 
Immunohistochemical staining for the proliferation marker Ki67 confirmed prostate and seminal 
vesicle tissues to be highly proliferative, as well as all metastatic deposits (Supplementary figure 15-
17). Immunohistochemical staining for probasin showed that probasin expression is lost as the 
tumour tissues become less differentiated and metastatic deposits usually did not express probasin 
(Supplementary figure 18-20). Normal liver tissue appears to stain positive for probasin, though this 
can be explained as a false positive due to the presence of Probasin-Related Antigen (PRB-RA) in 
rodent liver cells(34). The prostate tissues treated with GLV-1h153 appear to have retained more 
differentiation than the control tissues and more so in the tissues treated with the combination of 
GLV-1h153 and 131I. 
  
DISCUSSION 
We have shown that oncolytic NIS-expressing vaccinia virus exerted significant activity against 
prostate cancer as a single-agent, in combination with external beam radiotherapy, and with 
therapeutic radioiodide. VV-NIS had potent anti-tumour efficacy against prostate cancer cells in vitro 
which was most apparent at later time-points, presumably as a result of ongoing viral replication (Fig 
1). The presence of the NIS gene gave the virus the ability to accumulate radioiodide within infected 
cells and, importantly, we showed that resulted in DNA damage in uninfected bystander cells in 
close proximity (Fig 2). The observation that the bystander DU145 cells exhibited a greater number 
of γH2Ax foci could be explained by the cell cycle of the infected cells being arrested, compared to 
the bystander cells which are actively cycling and experiencing replication stress that would degrade 
single-strand breaks into double-strand breaks and thus result in more γH2Ax foci. The same effect 
was not seen in the other cell lines, perhaps simply because of biological variations in the rates of 
cell cycle or DNA repair mechanisms. This effect, which was seen in a 2-dimensional in vitro assay, 
was due to emission of β-particles by 131I and is likely to be a significant underestimate of what 
would occur in vivo within the densely packed 3-dimensional tumour environment. In combination 
with EBRT, viral oncolysis was not inhibited and the combination effectively reduced the clonogenic 
potential of irradiated cells (Figs 3 and 4) The mechanism of cell death involved signalling through 
apoptotic pathways. However, in contrast to our previous observations in melanoma cells that 
showed that vaccinia virus and radiation acted synergistically by modulating JNK/TNFα signalling 
(33), we did not see evidence of this effect in prostate cancer cell lines (Fig 5). This highlights the fact 
that different tumour types are likely to show different combinatorial effects with virus plus 
radiotherapy and/or chemotherapy.  
We also provided in vivo evidence that intratumourally delivered VV-NIS was capable of driving 
iodide uptake in xenograft tumours and that this translated to a powerful anti-tumour effect. 
Indeed, we were able to demonstrate that the combination of VV-NIS and radioiodide was capable 
of delaying tumour growth significantly and of achieving long-term control in PC3 xenograft tumours 
(Fig 6). These data were consistent with in vivo evidence of gene expression – measured by GFP 
imaging and radioiodide uptake assay (Fig 6). To evaluate off-target viral effects, viral luciferase was 
used to produce bioluminescent imaging of areas of viral replication. Viral replication was high in the 
tumour and undetectable in other organs, indicating little or no capacity for the virus to leak from 
the tumour to establish infection at other sites, even in immune deficient animals. Therefore there is 
no evidence to suggest that there would be any significant off-target accumulation of iodide in any 
organs other than perhaps the thyroid, which as previously mentioned has not caused adverse effect 
in these studies. Having demonstrated this in an immunodeficient animal model, we were keen to 
test the therapeutic effect in immunocompetent TRAMP mice. In these experiments, we were able 
to confirm that intravenously delivered virus significantly extended life-span, even as a single agent. 
Importantly, when combined with radioiodide long-term survival was further improved, quadrupling 
survival compared to control animals and with 50% of the combination group surviving at the day 
200 termination of the experiment (Fig 7). The 131I dose used in these in-vivo studies is scaled down 
from the typical human dose and is in the range used in similar studies(35, 36). It is notable that 
those animals that received 131I showed no sign of late adverse effects of the treatment, indicating 
that any undetected off target effects were minimal. This is reflected in clinical radiotherapy where 
131I is used in patients with thyroid gland in-situ on a regular basis without any long-term 
complications. Given that the TRAMP-C cell lines appeared relatively resistant to viral oncolysis, we 
hypothesise that the efficacy observed in the TRAMP model may be related to immune-mediated 
effects rather than direct oncolysis. The positive role of the immune system in the efficacy of 
oncolytic viruses has been reported in several recent studies(37-41) and certainly is an avenue 
requiring more research, in which immunocompetent models such as the TRAMP mice and novel 
immune-checkpoint inhibitors will be valuable. 
It had been our intention to test VV-NIS-driven radioiodide therapy combined with EBRT, but the 
efficacy of the individual component parts meant that this was not feasible.  However, based on the 
studies reported here, we believe that viral-mediated radioiodide therapy of prostate cancer has the 
potential to contribute significantly to the radiation dose delivered by EBRT. This would theoretically 
improve patient outcomes (e.g. progression-free and overall survival) by improving the ability of 
radiotherapy to secure locoregional control of prostate cancer. In addition, the selective replication-
competence of VV-NIS would ensure that normal tissue toxicity would be minimised. 
In summary, the data presented here contribute further evidence of single-agent efficacy of 
oncolytic vaccinia, but also point the way to further pre-clinical and clinical studies of oncolytic 
viruses in radio-virotherapeutic approaches. These further studies would build on the promising, but 
numerically limited, early-phase clinical studies utilising adenovirus and measles which, to date, have 
not explored the potential additional benefit of 131I therapy, but have successfully demonstrated 
functional NIS transgene expression using non-therapeutic imaging isotopes (18, 30).  In addition, 
the growing realisation that oncolytic virotherapy represents a form of “oncolytic immunotherapy” 
means that further translational studies of VV-NIS, radiotherapy and other immune therapies (e.g. 
checkpoint inhibitors) should be a priority for researchers in this field. Prostate cancer will be an 
excellent model system in which to investigate these therapies, given its accessibility for direct 
intratumoural injection and needle-core biopsy. 
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FIGURE LEGENDS 
Figure 1 
Prostate cancer cells were infected with GLV-1h153 and the reduction of proliferative capability was 
measured by MTT assay at 24, 48 and 72 hours post-infection. Standard errors of the mean are 
shown. Significance is the result of 2-Way ANOVA with Bonferroni multiple comparisons test, 
*P<0.05, **P<0.001, ***P<0.0001. 
 
Figure 2 
Functional assays were used to measure viral NIS expression. A. Representative confocal images of 
the effect of GLV-1h153 infection (VV), 2 Gy external beam radiotherapy (2 Gy RT), Combined GLV-
1h153 infection and radioiodide treatment (VV+131I), radioiodide treatment alone (131I) and 
combined GLV-1h153 and 2 Gy external beam radiotherapy (2 Gy RT + VV) on DNA double-strand 
breaks measured by γH2Ax foci in WPMY (Top) and DU145 (Middle) and PC3 (Bottom) cells. Blue: 
DAPI, Green: Viral GFP, White: H2Ax foci. White arrows mark the non-infected ‘bystander’ cells that 
have received DNA damage. B. Quantification of confocal images examining the distribution of H2Ax 
foci among subsets of cells. Untreated control (C), radioiodide treated (131I), 2 Gy external beam 
radiotherapy (RT), GLV-1h153 infection (VV) and combinations thereof. Standard errors are shown. 
Significance is the result of 2-Way ANOVA with Sidak’s multiple comparisons test, *P<0.05, 
**P<0.001, ***P<0.0001. C. Radioiodide uptake following GLV-1h153 infection at a range of 
multiplicities of infection (MOI), with and without the influence of external beam radiation (5 Gy) 
and potassium perchlorate (KClO4). Standard errors of the mean are shown. Significance is the result 
of 2-Way ANOVA with Bonferroni multiple comparisons test, *P<0.05, **P<0.001, ***P<0.0001. 
 
Figure 3 
Prostate cancer cells treated with GLV-1h153 4 hours after external beam irradiation. Reduction of 
proliferative capability measured by: A. MTT assay at 72 hours; and B. SRB cytotoxicity assay at 48 
hours. Standard errors of the mean are shown. Significance is the result of 2-Way ANOVA with 
Bonferroni multiple comparisons test, *P<0.05, **P<0.001, ***P<0.0001. C. Clonogenic capacity of 
cells treated with GLV-1h153 and external beam radiation. Significance is the result of 1-Way ANOVA 
with Tukey’s multiple comparisons test, *P<0.05, **P<0.001, ***P<0.0001. 
 
Figure 4 
Viral gene expression in GLV-1h153 infected cells treated with external beam radiotherapy. A. Viral 
β-galactosidase measured by CPRG assay at a range of MOI and radiation doses 24 hours after 
treatment. Standard errors of the mean are shown. Significance is the result of 2-Way ANOVA with 
Bonferroni multiple comparisons test, *P<0.05, **P<0.001, ***P<0.0001. B. Representative example 
of the colorimetric CPRG assay. Red shows viral β-galactosidase activity. 
 Figure 5 
Mechanisms of cell death in cells treated with GLV-1h153 and radiation. A. Caspase-3/7 activity 48 
hours post-treatment. Standard errors of the mean are shown. Significance is the result of 2-Way 
ANOVA with Bonferroni multiple comparisons test, *P<0.05, ***P<0.0001. B. Activation of apoptosis 
by cleavage of caspase-3 and phosphorylation of JNK in response to external beam radiation and 
GLV-1h153 infection at MOIs of 0, 0.01, 0.1 and 1. C. Induction of apoptosis in response to GLV-
1h153 infection (MOI 0.1), external beam radiotherapy (2 Gy), 131I (5 µCi) and combinations thereof, 
measured by γH2Ax expression, caspase-3 cleavage and PARP-1 cleavage. 
 
Figure 6 
In vivo GLV-1h153 gene expression and therapy. A. Gamma emissions from excised PC3 xenografts 
treated with intratumoural injection of 1x106 PFU GLV-1h153 and 1 mCi of 131I 48 hours later, 
alongside controls that received 131I only. B. Viral GFP expression in intratumourally treated 
xenografts. C. Long-term therapeutic effect of treatment with GLV-1h153 and 131I on PC3 xenografts. 
Kaplan-Meier plot significance is the result of log-rank (Mantel Cox) test. *P<0.05, **P<0.001. 
Tumour volume plot shows standard errors of the mean. D. Biodistribution of viral gene expression 
detected by viral encoded Renilla luciferase bioluminescence following intratumoural administration 
of GLV-1h153 in PC3 xenograft. 
 
Figure 7 
Efficacy of GLV-1h153 in TRAMP models. A. Confocal images of H2Ax foci resulting from DNA double 
strand breaks in TRAMP cells treated with GLV-1h153 and 131I. Blue: DAPI, Green: Viral GFP, White: 
γH2Ax foci. White arrows mark the non-infected ‘bystander’ cells that have received DNA damage. 
B. TRAMP cells treated with GLV-1h153 and external beam radiation. Reduction of proliferative 
capability was measured by MTT assay at 48 hours post-infection. Standard errors are shown. 
Significance is the result of 2-Way ANOVA with Bonferroni multiple comparisons test, *P<0.05, 
**P<0.001, ***P<0.0001. C. Long term survival of TRAMP mice bearing spontaneous prostate 
tumours and treated intravenously with 5x107 PFU GLV-1h153 (VV-NIS) and 1 mCi 131I (VV-NIS + 131I) 
(n=4). Kaplan Meier plot significance is the result of log rank (Mantel Cox) test. D. Representative 
examples of the histology of the above TRAMP mouse prostates, showing H&E staining and IHC for 
KI67 and probasin at the time of death. 
 
Supplementary Figure 1 
Detection of NIS mRNA in prostate cells infected with virus for 24 hours by qRT-PCR.  
 
Supplementary Figure 2 
An alternative analysis of by-stander effect by correlation of the quantified H2Ax foci and infected 
cells using the data presented in Figure 2B. 
Supplementary Figure 3 
Prostate cancer cells treated with GLV-1h153 following treatment with external beam radiation. 
Reduction of proliferative capability was measured by MTT assay at 24 and 48 hours. Standard errors 
of the mean are shown. Significance is the result of 2-Way ANOVA with Bonferroni multiple 
comparisons test, *P<0.05, **P<0.001, ***P<0.0001. 
 
Supplementary Figure 4 
Prostate cancer cells treated with alternative schedule of GLV-1h153 prior to external beam 
irradiation. Reduction of proliferative capability was measured by MTT assay at 24, 48 and 72 hours. 
Standard errors of the mean are shown. Significance is the result of 2-Way ANOVA with Bonferroni 
multiple comparisons test, *P<0.05, **P<0.001, ***P<0.0001. 
 
Supplementary Figure 5 
Viral gene expression in cells infected with GLV-1h153 4 hours after external beam irradiation. Viral 
β-galactosidase measured by CPRG assay at 48 and 72 hours post-treatment. Standard errors of the 
mean are shown. Significance is the result of 2-Way ANOVA with Bonferroni multiple comparisons 
test, *P<0.05, **P<0.001, ***P<0.0001. 
 
Supplementary Figure 6 
Viral gene expression in cells treated with alternative schedule of GLV-1h153 4 hours prior to 
external beam irradiation. Viral β-galactosidase measured by CPRG assay at 48 and 72 hours post-
treatment. Standard errors of the mean are shown.  
 
Supplementary Figure 7 
Densitometry quantification of the western blot images presented in Figure 5C. Presented as 
percentage change compared to the baseline level seen in control samples. 
 
Supplementary Figure 8 
Biodistribution of 131I 7 days post-intratumoural injection of 1x106 GLV-1h153 and 5 days post-
treatment with 1mCi 131I. 
 Supplementary Figure 9 
Biodistribution of viral gene expression. Detected by viral encoded Renilla luciferase 
bioluminescence following intratumoural administration of GLV1h153 in PC3 xenografts. 
 
Supplementary Figure 10 
Confocal images of H2Ax foci resulting from DNA double strand breaks in TRAMP-C3 cells treated 
with GLV-1h153 and 131I. Blue: DAPI, Green: Viral GFP, White: γH2Ax foci.  
 
Supplementary Figure 11 
Scarring at the location of healed pox lesions (Black arrows) on the tails of mice treated 
intravenously with GLV-1h153.  
 
Supplementary Figure 12 
Hematoxylin and eosin staining in tissues collected from the control group in the TRAMP mouse 
therapy experiment shown in Figure 7C. 
 
Supplementary Figure 13 
Hematoxylin and eosin staining in tissues collected from the VV-NIS treated group in the TRAMP 
mouse therapy experiment shown in Figure 7C. 
 
Supplementary Figure 14 
Hematoxylin and eosin staining in tissues collected from the VV-NIS + 131I treated group in the 
TRAMP mouse therapy experiment shown in Figure 7C. 
 
Supplementary Figure 15 
Immunohistochemical staining for Ki67 in tissues collected from the control group in the TRAMP 
mouse therapy experiment shown in Figure 7C. 
 
Supplementary Figure 16 
Immunohistochemical staining for Ki67 in tissues collected from the VV-NIS treated group in the 
TRAMP mouse therapy experiment shown in Figure 7C. 
 
Supplementary Figure 17 
Immunohistochemical staining for Ki67 in tissues collected from the VV-NIS + 131I treated group in 
the TRAMP mouse therapy experiment shown in Figure 7C. 
 
Supplementary Figure 18 
Immunohistochemical staining for probasin in tissues collected from the control group in the TRAMP 
mouse therapy experiment shown in Figure 7C. 
 
Supplementary Figure 19 
Immunohistochemical staining for probasin in tissues collected from the VV-NIS treated group in the 
TRAMP mouse therapy experiment shown in Figure 7C. 
 
Supplementary Figure 20 
Immunohistochemical staining for probasin in tissues collected from the VV-NIS + 131I treated group 
in the TRAMP mouse therapy experiment shown in Figure 7C. 
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